Biocon Announces Supplemental U.S. FDA Approval for Prefilled Autoinjector for YESINTEK

On August 18, 2026, Biocon Ltd. (“Biocon”) announced that its U.S. subsidiary has received supplemental U.S. FDA approval for YESINTEK® (ustekinumab-kfce) in a single-dose prefilled autoinjector, 45 mg/0.5 mL and 90 mg/mL. …
By: Goodwin